Oxford BioMedica To Manufacture More Doses Of AstraZeneca's COVID-19 Vaccine, Upgrades 2021 Outlook

Author: Vandana Singh | May 18, 2021 01:55pm

• Oxford BioMedica Plc (OTC: OXBDF) has raised its forecast for cumulative revenues from AstraZeneca Plc (NASDAQ: AZN) by the end of 2021 to more than £100 million from £50 million pounds earlier.
• The company did not provide any other details on its deal.
• Oxford BioMedica also expects significant growth in Group Operating EBITDA in the year ending 2021.
• AstraZeneca will purchase additional batches of Oxford BioMedica's COVID-19 vaccine in the second half of 2021, after successfully manufacturing large-scale batches of AstraZeneca's vaccine.
• Oxford BioMedica announced an 18 month supply agreement in September 2020 under a three-year supply and development agreement with AstraZeneca for large-scale commercial manufacture of the adenovirus vector-based COVID-19 vaccine, AZD1222.
• Price Action: AZN shares are up 0.57% at $56.20, and OXBDF shares are up 10.6% at $15.75 on the last check Tuesday.

Posted In: AZN OXBDF